Josine E Verhoeven1, Patricia van Oppen1, Dóra Révész1, Owen M Wolkowitz1, Brenda W J H Penninx1. 1. From the Department of Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, the Netherlands; and the Department of Psychiatry, University of California, San Francisco, School of Medicine, San Francisco.
Abstract
OBJECTIVE: Several cross-sectional studies have related depressive and anxiety disorders to shorter leukocyte telomere length (LTL) as an indicator of cellular aging. However, these studies have left many unresolved questions about underlying causality and ordering of associations. The objective of the present large, longitudinal study was to examine the relationship between depressive and anxiety disorders and LTL over a 6-year time period. METHOD: Data are from the Netherlands Study of Depression and Anxiety, including 2,292 patients with remitted and current diagnoses of depressive or anxiety disorders and 644 healthy control subjects. LTL was assessed using quantitative PCR and measured at baseline and after 6 years; depressive and anxiety disorder diagnoses and characteristics (course, duration, and severity) were determined at baseline and after 2, 4, and 6 years. RESULTS: Results showed that persons with remitted (B=-52.6) and current (B=-60.8) depressive or anxiety disorder had consistently shorter LTL compared with healthy control subjects across baseline and at the 6-year follow-up, remaining significant when controlling for lifestyle and somatic health variables. Changes in the course of depressive or anxiety disorder characteristics over 6 years, however, were not associated with different LTL attrition rates. CONCLUSIONS: This study confirmed robust associations of depressive and anxiety disorders with shorter telomeres, but interestingly, it did not demonstrate that depressive and anxiety disorders and LTL change together over time, suggesting the absence of a direct within-person relationship. Short LTL is suggested to be either a long-term consequence or an underlying vulnerability factor for depressive or anxiety disorders.
OBJECTIVE: Several cross-sectional studies have related depressive and anxiety disorders to shorter leukocyte telomere length (LTL) as an indicator of cellular aging. However, these studies have left many unresolved questions about underlying causality and ordering of associations. The objective of the present large, longitudinal study was to examine the relationship between depressive and anxiety disorders and LTL over a 6-year time period. METHOD: Data are from the Netherlands Study of Depression and Anxiety, including 2,292 patients with remitted and current diagnoses of depressive or anxiety disorders and 644 healthy control subjects. LTL was assessed using quantitative PCR and measured at baseline and after 6 years; depressive and anxiety disorder diagnoses and characteristics (course, duration, and severity) were determined at baseline and after 2, 4, and 6 years. RESULTS: Results showed that persons with remitted (B=-52.6) and current (B=-60.8) depressive or anxiety disorder had consistently shorter LTL compared with healthy control subjects across baseline and at the 6-year follow-up, remaining significant when controlling for lifestyle and somatic health variables. Changes in the course of depressive or anxiety disorder characteristics over 6 years, however, were not associated with different LTL attrition rates. CONCLUSIONS: This study confirmed robust associations of depressive and anxiety disorders with shorter telomeres, but interestingly, it did not demonstrate that depressive and anxiety disorders and LTL change together over time, suggesting the absence of a direct within-person relationship. Short LTL is suggested to be either a long-term consequence or an underlying vulnerability factor for depressive or anxiety disorders.
Authors: Shun-Chiao Chang; Jennifer Prescott; Immaculata De Vivo; Peter Kraft; Olivia I Okereke Journal: J Psychiatr Res Date: 2018-05-26 Impact factor: 4.791
Authors: Laura K M Han; Josine E Verhoeven; Audrey R Tyrka; Brenda W J H Penninx; Owen M Wolkowitz; Kristoffer N T Månsson; Daniel Lindqvist; Marco P Boks; Dóra Révész; Synthia H Mellon; Martin Picard Journal: Psychoneuroendocrinology Date: 2019-04-05 Impact factor: 4.905
Authors: J E Verhoeven; D Révész; M Picard; E E Epel; O M Wolkowitz; K A Matthews; B W J H Penninx; E Puterman Journal: Mol Psychiatry Date: 2017-03-28 Impact factor: 15.992
Authors: Mary C Vance; Eric Bui; Susanne S Hoeppner; Benjamin Kovachy; Jennifer Prescott; David Mischoulon; Zandra E Walton; Melissa Dong; Mireya F Nadal; John J Worthington; Elizabeth A Hoge; Paolo Cassano; Esther H Orr; Maurizio Fava; Immaculata de Vivo; Kwok-Kin Wong; Naomi M Simon Journal: Psychoneuroendocrinology Date: 2018-02-21 Impact factor: 4.905
Authors: Ezra Susser; Simon Verhulst; Jeremy D Kark; Pam R Factor-Litvak; Katherine Keyes; Per Magnus; Abraham Aviv Journal: Am J Psychiatry Date: 2016-11-01 Impact factor: 18.112
Authors: R Knutsen; V Filippov; S F Knutsen; G E Fraser; J Lloren; D Juma; P Duerksen-Hughes Journal: Biol Psychol Date: 2019-04-20 Impact factor: 3.251
Authors: Shun-Chiao Chang; Marta Crous-Bou; Jennifer Prescott; Bernard Rosner; Naomi M Simon; Wei Wang; Immaculata De Vivo; Olivia I Okereke Journal: Depress Anxiety Date: 2018-02-27 Impact factor: 6.505